

The MGH Center for Women's Mental Health has a special registry studying the use of atypical antipsychotic medications during pregnancy. All pregnant women ages 18-45 are eligible to enroll in the registry, whether or not they are taking these medications. This is a very important registry given the lack of information that exists about certain types of medications and their potential impact on the health of babies.

The MGH National Pregnancy Registry is the first hospital-based pregnancy registry for atypical antipsychotics in North America. The Registry is dedicated to evaluating the safety of atypical antipsychotic medications that may be taken by women during pregnancy to treat a wide range of mood, anxiety, or psychiatric disorders. The primary goal of this Registry is to determine the frequency of major malformations, such as heart defects, cleft lip, or neural tube defects, in infants exposed to atypical antipsychotics during pregnancy.

You are eligible to participate in the study if you are a pregnant woman aged 18-45 who is currently pregnant. Participation involves three brief phone interviews over a period of approximately eight months. **To participate:**

- call toll-free at <u>1-866-961-2388</u>,
- email registry@womensmentalhealth.org,
- or fill out this patient interest form to be contacted by a member of the research team

If you are a healthcare provider interested in referring someone to the Registry, please have your patient call or email, because this is a patient-initiated registry.

Please share this information with anyone who might benefit.